REGENXBIO Reports Q4/FY25 Results; Advances Pipeline Amidst Regulatory Setbacks

summarizeSummary

REGENXBIO reported Q4 and full year 2025 financial results, highlighting pipeline progress for Duchenne and a $100 million milestone from AbbVie, but also disclosed significant regulatory setbacks including clinical holds and a Complete Response Letter for its MPS II and MPS I gene therapy programs.

check_boxKey Events

• Q4 and Full Year 2025 Financial Results

  Reported full year 2025 revenues of $170.4 million (up from $83.3 million in 2024) and a net loss of $193.9 million (improved from $227.1 million in 2024). Cash, cash equivalents, and marketable securities stood at $240.9 million as of December 31, 2025.

• Cash Runway Extended

  The company expects its current cash position to fund operations into early 2027, based on current operational plans and excluding potential milestone payments or non-dilutive funding.

• RGX-202 (Duchenne) Program Advances

  Reported positive 18-month functional data from the Phase I/II AFFINITY DUCHENNE trial, with additional data expected on March 11, 2026. Pivotal topline data is anticipated in early Q2 2026, with a pre-BLA meeting planned for mid-2026.

• Sura-vec (ABBV-RGX-314) Milestones

  Expected to receive a $100 million milestone payment from AbbVie upon dosing the first patient in the pivotal Phase IIb portion of the NAAVIGATE study for diabetic retinopathy, anticipated in Q2 2026. Topline pivotal data for wet AMD (subretinal delivery) is expected in Q4 2026.

auto_awesomeAnalysis

REGENXBIO reported mixed financial results for Q4 and full year 2025, with increased revenues driven by partnerships but a continued net loss. The company's cash position of $240.9 million is expected to fund operations into early 2027. Operationally, the company announced positive 18-month data for its Duchenne muscular dystrophy program (RGX-202) with pivotal data expected early Q2 2026. A significant positive is the anticipated $100 million milestone payment from AbbVie upon dosing the first patient in the pivotal Phase IIb/III trial for diabetic retinopathy (sura-vec), expected in Q2 2026. However, this positive news is significantly offset by major regulatory setbacks for its MPS II (RGX-121) and MPS I (RGX-111) programs, including clinical holds and a Complete Response Letter (CRL) from the FDA for RGX-121. Investors should weigh the promising advancements and non-dilutive funding against the substantial regulatory hurdles for other key pipeline assets.